top of page
Home
Calvine Healthcare
Calvine Sustainables
Equity Research
Basilea
Blog
Contact
Â
Use tab to navigate through the menu items.
All Posts
Search
Andrew Keith
Aug 29, 2024
Basilea research report
Brian White
Aug 27, 2024
Cresemba's market exclusivity extension
Brian White
Aug 13, 2024
Gaining momentum in H1 2024
Brian White
May 16, 2024
Basilea - Cresemba APAC milestone
Brian White
May 3, 2024
Basilea - Fleshing out Zevtera
Brian White
Apr 4, 2024
Zevtera FDA approval
Andrew Keith
Feb 28, 2024
Basilea research report
Brian White
Feb 13, 2024
Basilea full-year results - Strong execution
Brian White
Jan 19, 2024
Basilea - Cresemba LatAm milestone
Brian White
Jan 15, 2024
Basilea adds another antibiotic programme
Brian White
Jan 5, 2024
Basilea portfolio update
Brian White
Dec 11, 2023
Basilea - Paediatric Cresemba approval
Brian White
Nov 13, 2023
Basilea - Fosmanogepix acquired
Brian White
Oct 31, 2023
Basilea - Novel antibacterial acquired
Andrew Keith
Oct 19, 2023
Basilea antifungal acquistion
Andrew Keith
Oct 2, 2023
FDA accepts ceftobiprole's NDA
Brian White
Sep 28, 2023
Key ceftobiprole data published
Andrew Keith
Sep 14, 2023
Basilea research report
Brian White
Aug 15, 2023
Basilea - H1 results and upgrade
Brian White
Aug 4, 2023
Basilea - ceftobiprole filed for US approval
bottom of page
